EYEN Aug 2024 5.000 call
- Business Wire
NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
EMERYVILLE, Calif. & NEW YORK, July 01, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare products, and Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, have commenced activities under a previously announced co-promotion agreement.
- GlobeNewswire
Eyenovia Announces Pricing of $5M Registered Direct Offering
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities purchase agreement with an institutional investor and its current largest stockholder, providing for the purchase and sale of 7,575,757 shares of common stock, and warrants to purchase up to 7,575,757 shares of common stock (the "Offering"). The combined offering price for each share of common stock a
- Zacks
All You Need to Know About Eyenovia (EYEN) Rating Upgrade to Buy
Eyenovia (EYEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
